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Background: Chronic low back pain can be associated with the pathological ingrowth of blood vessels
and nerves into intervertebral discs (IVDs). The notochord patterns the IVD during development and is a
source of anti-angiogenic soluble factors such as Noggin and Chondroitin sulfate (CS). These factors may
form the basis for a new minimally invasive strategy to target angiogenesis in the IVD.
Objective: To examine the anti-angiogenic potential of soluble factors from notochordal cells (NCs) and
candidates Noggin and CS under healthy culture conditions and in the presence of pro-inﬂammatory
mediators.
Design: NC conditioned media (NCCM) was generated from porcine NC-rich nucleus pulposus tissue. To
assess the effects of NCCM, CS and Noggin on angiogenesis, cell invasion and tubular formation assays
were performed using human umbilical vein endothelial cells (HUVECs) ± tumor necrosis factor alpha
(TNFa [10 ng/ml]). vascular endothelial growth factor (VEGF)-A, MMP-7, interleukin-6 (IL-6) and IL-8
mRNA levels were assessed using qRT-PCR.
Results: NCCM (10 & 100%), CS (10 and 100 mg) and Noggin (10 and 100 ng) signiﬁcantly decreased cell
invasion of HUVECs with and without TNFa. NCCM 10% and Noggin 10 ng inhibited tubular formation
with and without TNFa and CS 100 mg inhibited tubules in Basal conditions whereas CS 10 mg inhibited
tubules with TNFa. NCCM signiﬁcantly decreased VEGF-A, MMP-7 and IL-6 mRNA levels in HUVECs with
and without TNFa. CS and Noggin had no effects on gene expression.
Conclusions: We provide the ﬁrst evidence that soluble factors from NCs can inhibit angiogenesis by
suppressing VEGF signaling. Notochordal-derived ligands are a promising minimally invasive strategy
targeting neurovascular ingrowth and pain in the degenerated IVD.
© 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Chronic low back pain affects 70e85% of the population at some
point during their lives1 and is the leading cause of disability
worldwide2 with costs exceeding $100 billion a year in the United
States3 alone. Back pain is strongly associated with intervertebral
disc (IVD) degeneration and the development of strategies to target
discogenic back pain is a research priority. Current therapies are. Purmessur, Icahn School of
ox 1188, New York, NY 10029,
(M.C. Cornejo), Samuel.cho@
.edu (C. Giannarelli), James.
ssm.edu (D. Purmessur).
ternational. Published by Elsevier Lrestricted to invasive surgical procedures or therapies that focus on
temporary analgesia rather than targeting the mechanisms un-
derlying the source of the pain4. The ingrowth of nociceptive nerve
ﬁbers and blood vessels has been identiﬁed in symptomatic IVDs5.
Thus neurovascular ingrowth in the IVD is a novel and underex-
plored therapeutic target.
The IVD is the largest avascular organ in the body, resulting in a
hypoxic cellular microenvironment6. Hypoxia promotes neo-
angiogenesis in health (wound healing) and disease (cancer)7
posing the question: how can the healthy hypoxic IVD maintain
an avascular structure if it is surrounded by vascularized spinal
tissues? Proteoglycans such as aggrecan inhibit endothelial
migration in vitro and the healthy intact IVD is a rich-source of
these large aggregating matrix proteins8,9. Such proteoglycans alsotd. All rights reserved.
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magnitudes of pressurization in the IVD may inhibit blood vessels
from growing in. However during degeneration, there is an increase
in structural disruption (annular ﬁssures), depletion of pro-
teoglycans, and loss of pressurization6. These changes, combined
with the hypoxic nature of the IVD, provide a permissive micro-
environment that favors neo-angiogenesis. Studies have demon-
strated that nerve ﬁbers expressing the nerve growth factor (NGF)
receptor, TrkA grow alongside blood vessels expressing the ligand
NGF in tissue isolated from painful discs5.
The diseased IVD is a source of key angiogenic factors such as
vascular endothelial growth factor (VEGF), tumor necrosis factor
alpha (TNFa), interleukin-8 (IL-8), IL-6 and MMP-7 and such factors
may play a role in neo-angiogenic processes in painful disc
degeneration10e16. VEGF is a key angiogenic growth factor that
stimulates endothelial cell proliferation, migration, and blood
vessel formation7. It is modulated by pro-inﬂammatory cytokines
and hypoxia inducible proteins in vitro17,18. TNFa inﬂuences
angiogenesis through the up-regulation of pro-angiogenic factors
VEGF, IL-6, and MMP-7 in IVD cells14,19e21 and also induces angio-
genic sprouting in endothelial cells15. Other cytokines such as IL-6
can stimulate the production of VEGF22 while IL-8 enhancesFig. 1. Schematic of the hypothetical model: treatment of painful neurovascular ingrowth
Noggin, can inhibit angiogenesis via inhibition of endothelial cell invasion and blood vessel fo
pro-angiogenic cytokines VEGF, MMP-7, IL-6, and IL-8. We propose that vascular ingrowth
genesis is an important clinical target that could result in therapies with sustained efﬁcacyendothelial cell survival, proliferation, and migration23. Matrix
enzymes like MMP-7 promote angiogenesis through the release
and activation of pro-angiogenic cytokines sequestered in extra-
cellular matrix and accelerate endothelial cell proliferation and
vessel formation24.
Recapitulation of the processes that occur during embryonic
patterning of the IVD may help inform symptom-modifying treat-
ments for painful disc degeneration. The notochord is an embryonic
structure of chordates that patterns the spine25 and secretes anti-
angiogenic factors such as Noggin and Chordin26,27. The noto-
chord also synthesizes proteoglycans, including chondroitin
sulfated (CS) proteoglycans, which are involved in repulsion of
dorsal root ganglion cells28. Such proteoglycans can also inhibit
angiogenesis in adults29. Notochordal cells (NCs) isolated from the
immature nucleus pulposus (NP) secrete soluble factors that can
inhibit neurite outgrowth while maintaining neural cell viability30
and were also reported to have anti-inﬂammatory effects sup-
pressing IL-6, IL-8, and nitric oxide synthesis in the IVD31. In this
work, we evaluate if NCs secrete soluble factors that can target
neovascularization associated with discogenic back pain32.
We propose a hypothetical model describing how NC condi-
tioned medium (NCCM) can be utilized to target neurovascular. Soluble factors found in NCCM from the healthy immature IVD, speciﬁcally CS and
rmation in both a (1) healthy and (2) degenerate environment through (3) inhibition of
is the precursor to subsequent nerve ingrowth and pain and that inhibition of angio-
.
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didates (Fig. 1). While the inhibitory effects of aggrecan derived
from adult human NP tissue and non-degenerate human NP cells
themselves have been assessed on neurovascular growth in vitro, it
remains unknown if NCCM would have similar affects8,33. Hy-
pothesis 1 is that NCCM contains soluble factors including CS and
Noggin that can inhibit angiogenesis through suppression of
endothelial cell invasion and blood vessel formation (Fig. 1). Pro-
inﬂammatory mediators are increased in painful degenerate IVDs
and are also associated with angiogenesis. Hypothesis 2 is that
NCCM, Noggin and CS can suppress endothelial invasion and blood
vessel formation in the presence of TNFa. Hypothesis 3 is that
NCCM and therapeutic candidates inhibit angiogenesis through
suppression of pro-angiogenic factors VEGF, MMP-7, IL-8 and IL-6.
Angiogenesis and nerve ingrowth are often integrated pro-
cesses34. We propose that neo-angiogenesis is an initiator of dis-
cogenic back pain as it promotes sensory nerve ingrowth into the
IVD and suggest that direct repulsion of neovascularization may be
an important part of therapies to relieve discogenic pain.
Methods
Generation of NCCM
NCCM was generated from NC-rich NP tissue aseptically
dissected from eight porcine spines (6e8 weeks of age) obtained
within 24 h of death (Animal Facility Research 87 Inc., Boylston, MA,
USA). The isolated tissue was incubated in high glucose DMEM, 1
insulin transferrin & selenium, salt solution (5 M NaCl/0.4 M KCl)
and 50 mg/ml ascorbic acid for 4 days in hypoxia (1% O2, 5% CO2 and
37C). NCCM was ﬁltered using 3000 MW Amicon Ultra-15 Cen-
trifugal Filter (Millipore, #UFC900324) to retain soluble factors and
to remove small metabolites and waste products. The ﬁltrate was
re-suspended in Medium 200PRF (Med200) (Life Technologies,
#M200PRF500) and stored at 80C.
Human umbilical vein endothelial cell (HUVEC) culture
Primary HUVECs (Life Technologies, #C01510C) were cultured
according to the manufacturer's instructions in Medium 200 sup-
plemented with Low Serum Growth Supplement (LSGS) (Life
Technologies, #S00310) until 80% conﬂuent. The ﬁnal concentra-
tions of the components in the supplemented medium (basal me-
dium) were 2% fetal bovine serum, 1 mg/ml hydrocortisone, 10 ng/
ml human epidermal growth factor, 3 ng/ml basic ﬁbroblast growth
factor, and 10 mg/ml heparin. HUVECs at passages 1e3were used for
all experiments.
Effects of NCCM on endothelial cell invasion
HUVECs were serum-starved (0% FBS, 0.2% BSA) overnight and
seeded in Basal mediumwithout FBS at a density of 30,000 cells per
well into the top insert plate of a 96 well Millipore Multiscreen-MIC
Plate (8.0 mm pores, Millipore, #MAMIC8S10) pre-coated with 50 ml
Matrigel (BD Biosciences, #356234) at a concentration of 800 mg/
ml. HUVECs were incubated for 16 h (5% CO2 and 37C) with the
following treatment conditions added to the receiver plate in
quadruplicate: (1) Basal medium and (2) NCCM at 10% and 100%
doses (n ¼ 4). All conditions were supplemented with FBS at a ﬁnal
concentration of 5%, to serve as a chemo-attractant, and LSGS. After
16 h, the receiver plate was removed, and the cells in the insert
plate were incubated for 15 min with 0.1% 2 mM Ethidium
Homodimer-1 stock (Life Technologies, #E1169) and 0.2% 4 mM
Calcein AM stock (Life Technologies, #C1430) in Basal medium
without FBS. Twenty images of the bottom surface of the insertplate membrane were taken per group at 5 magniﬁcation and
percent area ﬂuorescence as a measurement of cell invasion
analyzed (see Image analysis).
Effects of NCCM on endothelial tubular formation
HUVECs were seeded at 80,000 cells per well in a 24 well plate
coated with 100 ml Geltrex LDEV-Free, a reduced growth factor
basement membrane matrix (Life Technologies, #A1413202).
HUVECs were incubated for 24 h (5% CO2, 37C) with the following
treatment conditions in triplicate: (1) Basal medium and (2) NCCM
(n ¼ 4) at 10% and 100% doses. All groups were supplemented with
LSGS, which together with Geltrex, induced tubular formation.
After 24 h, cells were incubated for 15 min with Ethidium and
Calcein as above. Fifteen images were taken per group at 5
magniﬁcation and tubule length analyzed (see Image analysis).
CS and Noggin additive and blocking studies on endothelial cell
invasion and tubular formation
Additive studies examined the following treatment conditions:
(1) Basal medium, (2) CS (Sigma, #C9819) at 10 and 100 mg/ml29,
and (3) Noggin (R&D Systems #6057-NG-025/CF) at 10 and 100 ng/
ml35, for both the cell invasion assay and tubular formation assays.
For blocking studies, NCCM and basal medium (n ¼ 4) were treated
with 0.05 U/ml Chondroitinase ABC (Chon-ABC) (Sigma #C3667) at
37C for 30 min to digest CS and dermatan sulfate (DS). Our pre-
vious work has shown that CS forms the major glycosaminoglycan
(GAG) in NCCM30. HUVECs were then treated with: (1) Basal me-
dium, (2) Basal medium with Chon-ABC, (3) NCCM (100%), and (4)
NCCM (100%) with Chon-ABC, for both the cell invasion and tubular
formation assays. Currently, there is no direct method available to
inactivate or block Noggin in conditioned media and so a blocking
study for Noggin could not be performed.
Effects of NCCM, CS and Noggin on cell viability
Images (15 images @ 5magniﬁcation) of Calcein (green ¼ live
cells) and Ethidium (red¼ dead cells) stained endothelial cells from
the tubular formation assay were used to assess cell viability.
Percent live cells were quantiﬁed from the combined totals of live
and dead cells using Image J.
Effects of NCCM, CS and Noggin on endothelial cell invasion, tubular
formation and gene expression in the presence of TNFa
HUVECs were seeded, incubated and analyzed as above for the
cell invasion and tubular assays. Groups included (1) Basal medium,
(2) NCCM at 10% and 100% doses, (3) CS at 10 and 100 mg/ml and (4)
rhNoggin at 10 and 100 ng/ml, with or without recombinant human
TNFa (Life Technologies, #PHC3015) (10 ng/ml) including a TNFa
control group. For assessment of gene expression, HUVECs from the
tubular assay were lysed with Trizol Reagent, RNA extracted
(MachereyeNagel, #740902.50) and cDNA synthesized (Life Tech-
nologies, #11754-250) according to manufactures instructions.
qRT-PCR was performed using Taqman Gene Expression Assays
(Life Technologies, #4331182) for VEGF (hs00900055_m1), MMP-7
(hs01042796_m1), IL-6 (hs00985639_m1), IL-8 (hs00174103_m1)
and 18S (hs99999901_s1) using DDCT method36. DDCT are
expressed as the mean fold change normalized to the house-
keeping gene 18S and either to the Basal or TNFa control, respec-
tively. To verify that an inﬂammatory microenvironment had been
induced by addition of TNFa we performed an enzyme linked
immunosorbent assay (ELISA) speciﬁc for human TNFa, IL-1b, IL-6,
IL-8 (MSD N45025B-1) on Basal and TNFa control media samples.
Fig. 2. Image analysis of angiogenesis assays: cell invasion and tubular formation. Cell invasion is an in vitro measure of cell migration through a matrix barrier that occurs during
angiogenesis in vivo. Tubular formation represents the organization and assembly of endothelial cells into blood vessels. Representative images used to analyze HUVEC invasion and
tubular formation assays. Images were captured at 5 magniﬁcation using a Zeiss inverted microscope and Axiovision software after staining with green-ﬂuorescent calcein-AM
and red-ﬂuorescent ethidium homodimer-1. Zeiss Auto Measurement Program was used to (1) deﬁne and measure the area of ﬂuorescence to determine cell invasion and (2)
measure the length of tubules excluding branching points of formed tubular networks, without human bias.
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NGF-beta sandwich ELISA (Peprotech # 900-K60) was also per-
formed on Basal and TNFa control media samples.
Image analysis
To quantify cell invasion and tubular formation assays, images
were captured using a ﬂuorescent inverted Zeiss microscope
(Emission/excitation; Calcein ¼ 494/517 nm and ETH ¼ 528/
617 nm). Zeiss Auto Measurement Software was used to determine
the percent area ﬂuorescence for the invasion assay and length of
tubules for the tubular assay (Fig. 2). The “Area percent” Zeiss AutoFig. 3. NCCM, CS and Noggin inhibit endothelial cell invasion. HUVECs cultured under bas
bottom of the well insert. Addition of NCCM at both 10% and 100% signiﬁcantly inhibited end
Basal [85.67, 92.78], NCCM 10 [44.78, 59.95], NCCM 100 [52.37, 67.27]). Addition of CS at 10 a
(CI: Basal [47.83, 57.50], CS10 [14.18, 27.98], CS100 [19.15, 27.07]). Addition of Noggin at 10 an
(CI: Basal [60.63, 76.48], Noggin10 [28.42, 38.83], Noggin100 [35.06, 60.31]). All scale barsMeasurement Field Feature was used to determine percent area of
ﬂuorescence and is deﬁned as the total area of ﬂuorescence in
relation to the area of the total image. The “Fibrelength” Zeiss Auto
Measurement Region Feature was used to determine the length of
tubules and is deﬁned as the length of a ﬁber-like region in the unit
of the scaling assigned to the image.
Statistics
As a Gaussians distribution could not be assumed, a non-
parametric multiple comparison KruskaleWallis test with a post
hoc Dunns test was performed between Basal and the respectiveal conditions invaded through the Matrigel basement membrane and migrated to the
othelial cell invasion compared to basal control, P ¼ 0.0024 (A) (error bars represent CIs:
nd 100 mg signiﬁcantly inhibited cell invasion compared to basal control, P ¼ 0.0032 (B)
d 100 ng signiﬁcantly inhibited cell invasion compared to basal control, P ¼ 0.0021 (C)
correspond to 200 mm.
Fig. 4. NCCM, CS, and Noggin inhibit endothelial tubular formation. HUVECs cultured under basal conditions demonstrated formation of a clearly intact tubular network with
numerous extending tubules. Addition of NCCM at both 10% and 100% concentration signiﬁcantly inhibited endothelial tubular formation compared to basal control with tubules
demonstrating a fragmented appearance, P ¼ 0.0244 (A) (error bars represent CI: Basal [102.2, 203.2], NCCM10 [72.8, 100.5], NCCM100 [69.22, 118.1]). Addition of CS at
100 mg signiﬁcantly inhibited tubular formation compared to basal control, P ¼ 0.0349 (B) (CI: Basal [102.2, 203.2], CS10 [74.02, 144.9], CS100 [37.84, 182.1]). Addition of Noggin at
10 ng signiﬁcantly inhibited tubular formation compared to basal control, P ¼ 0.0343 (C) (CI: Basal [102.2, 203.2], Noggin 10 [60.31, 104.2], Noggin 100 [103.2, 139.2]). All scale bars
correspond to 200 mm.
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Noggin 100 ng) for tubular, cell invasion and gene expression as-
says. A MannWhitney U test was used to assess protein expression
(IL-1b, TNFa, IL-6 and IL-8) comparing TNFa treatment with Basal
control. For NCCM, biological replicates were n ¼ 4, however, as
treatments with CS and Noggin groupswere not based on biological
replicates, the mean value of 3 and 4 experimental replicates were
used for tubular and invasion assays, respectively (Supplemental
data 1). All values are expressed as the mean ± the 95% conﬁ-
dence interval (95% CI). P values <0.05 were considered signiﬁcant.Results
NCCM inhibits cell invasion and endothelial tubular formation
NCCM at both 10% and 100% doses signiﬁcantly inhibited cell
invasion compared to Basal controls (P ¼ 0.0024) [Fig. 3(A)]. Both
doses of NCCM signiﬁcantly decreased the length of tubules and
increased the fragmentation of tubular networks compared to Basal
control (P ¼ 0.0244) [Fig. 4(A)].CS and Noggin inhibit endothelial cell invasion and tubular
formation
To investigate the role of CS, additive studies were performed
with doses of 10 and 100 mg/ml. Both doses signiﬁcantly inhibited
cell invasion (P ¼ 0.0032) [Fig. 3(B)]. CS at 100 mg/ml signiﬁcantly
decreased the length of tubules formed compared to Basal controls
(P ¼ 0.0349), however, CS at 10 mg/ml did not signiﬁcantly inhibit
tubule length [Fig. 4(B)]. When examining the effects of Noggin,both doses (10 and 100 ng/ml) signiﬁcantly inhibited cell invasion
(P ¼ 0.0021) [Fig. 3(C)]. Noggin at 10 ng/ml signiﬁcantly decreased
the length of tubules formed compared to Basal controls
(P ¼ 0.0343), however, Noggin at 100 ng/ml did not inhibit tubule
length [Fig. 4(C)].
Blocking studies for CS were performed in which NCCM (100%)
was digested with Chon-ABC and used to treat HUVECs for both the
cell invasion and tubular formation assays. NCCM signiﬁcantly
inhibited cell invasion and decreased the length of tubules
compared to Basal control, Basal control with Chon-ABC, and NCCM
with Chon-ABC (P ¼ 0.0070 and P ¼ 0.0193, respectively). NCCM
treated with Chon-ABC restored cell invasion and tubule length to
basal levels with no differences between Basal control, Basal control
with Chon-ABC, and NCCM with Chon-ABC in either assay (Fig. 5).NCCM, CS and Noggin maintain cell viability
NCCM and Noggin at both doses and CS at 10 mg/ml did not
demonstrate any negative effects on cell viability as all groups had
>90% live cells with no signiﬁcant differences compared to Basal
control (Supplemental data 2). However, CS at 100 mg/ml decreased
cell viability with 67% live cells and was signiﬁcantly lower than all
groups, including basal (P ¼ 0.0026).NCCM, CS and Noggin inhibit cell invasion and tubular formation in
the presence of TNFa
Angiogenesis and inﬂammation occur simultaneously in the
painful degenerate IVD. We therefore investigated whether NCCM,
CS and Noggin could inhibit cell invasion and tubular invasion in
Fig. 5. CS-derived from NCCM inhibits angiogenesis. NCCM was digested with Chon-ABC, to deplete CS, since CS was previously shown to be the predominant GAG in NCCM31.
HUVECs cultured in Basal or Basal conditions with Chon ABC invaded through the Matrigel basement membrane and formed intact tubular networks (AeD). Addition of NCCM at
100% signiﬁcantly inhibited endothelial cell invasion and tubular formation compared to all groups, P ¼ 0.007 and P ¼ 0.0193, respectively. (E, F). Digestion of CS restored cell
invasion and tubular formation to basal levels (G, H). Quantiﬁcation of cell invasion and tubular length assays (I, J) (for cell invasion: error bars represent CI: Basal [70.91, 78.45],
Basal Chon ABC [67.81, 89.16], NCCM [36.54, 49.77], NCCM Chon ABC [61.36, 82.66] and tubular formation CI: Basal [216.5, 280.8], Basal Chon ABC [214.8, 307.3], NCCM [99.67, 158.4],
NCCM Chon ABC [212.7, 255.9]). All scale bars correspond to 200 mm.
M.C. Cornejo et al. / Osteoarthritis and Cartilage 23 (2015) 487e496492the presence of TNFa. TNFa induced a pro-inﬂammatory environ-
ment involving the up-regulation of multiple pro-inﬂammatory
cytokines (IL-1b, TNFa, IL-6 and IL-8) in HUVECs (Supplemental
data 3), as would be expected in the degenerated IVD microenvi-
ronment. NGF protein expression was not detected in any of the
Basal of TNFa treated media samples. There were no signiﬁcant
differences in cell invasion between Basal and TNFa controls. NCCM
in the presence of TNFa at both 10% and 100% suppressed cell in-
vasion compared to TNFa controls (P ¼ 0.0002). Similar inhibitory
effects were observed for CS at 10 and 100 mg and Noggin at 10 and
100 ng also in the presence of TNFa (Fig. 6) (P ¼ 0.0002 and
P ¼ 0.0003, respectively). When assessing effects on tubular for-
mation, HUVECs in Basal or TNFa conditions demonstrated intact
tubular networks with no differences between these two groups
(Fig. 7). However, NCCM, CS and Noggin at doses of 10% and 10 mg
and 10 ng, respectively, signiﬁcantly inhibited tubular formation
compared to TNFa controls (P ¼ 0.0009, P ¼ 0.0190 and P ¼ 0.0149,
respectively).
NCCM inhibits the expression of pro-angiogenic markers VEGF,
MMP-7, IL-6 and IL-8
To examine the mechanisms through which NCCM might be
inducing its inhibitory effects, we investigated the gene expression
of VEGF, MMP-7, IL-6 and IL-8. Under Basal conditions, NCCM
(100%) signiﬁcantly down-regulated all genes apart from IL-8
compared to Basal control (P ¼ 0.0256, P ¼ 0.0201 and
P ¼ 0.0283, respectively) (Table I). Noggin and CS had no effects onpro-angiogenic genes under Basal or TNFa conditions. In the
presence of TNFa, NCCM demonstrated signiﬁcant decreases in
VEGF, MMP-7, IL-6 and IL-8 expression compared to the TNFa
control (P ¼ 0.0140, P ¼ 0.0162, P ¼ 0.0346 and P ¼ 0.0346,
respectively) (Table I and Supplemental data 4).
Discussion
This is the ﬁrst study to demonstrate that soluble factors from
the immature NC-rich porcine NP (NCCM) can inhibit angiogenic
processes in vitro, suggesting that NC-derived factors may be har-
nessed and used to treat vascular ingrowth. We investigated can-
didates CS and Noggin, previously identiﬁed in the notochord and
observed inhibition of endothelial invasion and tubular formation
at similar magnitudes to that of NCCM. NCCM itself as a potential
therapeutic intervention has limitations as the immature NC-rich
human IVD transitions into a chondrocyte-like NP-rich tissue at
adolescence25; so isolation of candidates CS and Noggin offer a
more targeted approach. Vascular ingrowth occurs in painful
degenerate IVDs in the presence of pro-inﬂammatory cytokines20
and we demonstrated that NCCM could also inhibit angiogenesis
in the presence of TNFa further highlighting the therapeutic po-
tential of these ligands. NCCM decreased the expression IL-6, IL-8,
MMP-7, and VEGF in endothelial cells both in the presence and
absence of TNFa, suggesting that NCCM may inhibit angiogenesis
through suppression of these pro-angiogenic genes. These results
support our hypothetical model in which soluble factors from the
notochord can be utilized to inhibit vascularization suggesting they
Fig. 6. NCCM, CS and Noggin inhibit cell invasion in the presence of TNFa. HUVECs cultured with TNFa demonstrated no signiﬁcant differences in cell invasion compared to basal
controls. Addition of NCCM at 10% and 100% signiﬁcantly decreased invasion compared to TNFa controls, P ¼ 0.0002 (A) (error bars represent CI: Basal [49.26, 77.17], B þ TNF [84.93,
93.27], NC10 þ TNF [36.58, 53.72] and NC100 þ TNF [28.48. 50.90]. Addition of CS and Noggin at both doses demonstrated similar effects, with signiﬁcant decreases in cell invasion
compared to TNFa controls, P ¼ 0.0002, P ¼ 0.0003, respectively (B, C) (for CS, CI: Basal [70.96, 79.91], B þ TNF [80.38, 84.30], CS10 þ TNF [39.78, 54.82] and CS100 þ TNF [50.60,
53.06] and for Noggin CI: Basal [62.50, 72.68], B þ TNF [81.59, 88.49], Nog10 þ TNFa [47.18, 66.16] and Nog100 þ TNFa [39.15, 60.68]. All scale bars correspond to 200 mm.
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degenerate IVD.
To assess the effects of NCCM on angiogenic mechanisms
in vitro, we used the cell invasion and tubular formation assays. The
cell invasion assays tests HUVECs ability to break down and invade
the matrix towards a chemo-attractant and the tubular formation
assay tests HUVECs ability to form tubulesmimicking the formation
of vessels in vivo13,37. NCCM inhibited both cell invasion and tubular
formation and these effects were largely dose independent for the
invasion assay, however, dose effects were observed for the tubular
assay; 100 mg CS and 10 ng Noggin exerted the greatest inhibitory
effects in basal conditions. Interestingly dose effects were also
observed for the tubular assay in the presence of TNFa, however,
signiﬁcant changes were observed for NCCM 10%, 10 mg CS
including 10 ng Noggin. It is possible to speculate that dose effects
of CS and Noggin for the tubular assay but not invasion assay
including variations between basal and inﬂammatory conditions
may be attributed to differences in chemotactic (cell invasion) vs
cellecell interactions (tubular formation) for these ligands, which
are likely altered in an inﬂammatory microenvironment. We
observed minimal effects on HUVEC cell viability in the presence of
NCCM, CS and Noggin, with the exception of CS at 100 mg sug-
gesting that NC-derived soluble factors are largely not cytotoxic.
However, these factors warrant further investigation in 3D organ
culture and animal models to conﬁrm safety and efﬁcacy.
The therapeutic potential of soluble factors from the notochord
has been highlighted by several studies. NCs co-cultured with
bovine NPCs demonstrate increased proteoglycan synthesis andCTGF/CCN2 was identiﬁed as the soluble factor responsible for the
observed effects38. NCCM can rescue degenerate human NP cells
and differentiate humanMSCs toward a healthy NP phenotype39,40.
Prior studies on NCCM focused primarily on the anabolic but not
the symptom-modifying potential of NC-derived factors. NCs have
anti-inﬂammatory and protective effects with the ability to
decrease expression of IL-6, IL-8, and nitric oxide synthase31 as well
as inhibit cell death and apoptosis in IVD cells in vitro41. We
observed that NCCM could inhibit endothelial cell invasion and
tubular formation in the presence of TNFa conﬁrming the anti-
inﬂammatory effects of NC derived factors and their ability to
function in the presence of TNFa which stimulated production of
multiple pro-inﬂammatory cytokines, many of which have been
detected in the degenerate human IVD16. Our previous work has
shown that NCCM inhibits neurite outgrowth from both neuro-
blastoma and DRG cells whilst maintaining cell viability and that CS
is a factor in NCCM responsible for these inhibitory effects30.
Together, these results demonstrate that NCCM has both anti-
neuronal and anti-angiogenic potential as well as structure-
modifying properties which can be used to target the degenerate
and painful IVD32.
CS is a sulfated GAG that is an essential component of pro-
teoglycans42 and is abundant in the healthy IVD but decreases with
age and degeneration43. CS derived from the notochord repulses
axonal elongation from dorsal root ganglion cells during develop-
ment28. CS has been successfully used as an anti-inﬂammatory in
osteoarthritis to prevent joint space narrowing and reduce joint
swelling44. However, the clinical potential of CSmay bemoremixed
Fig. 7. NCCM, CS and Noggin inhibit tubular formation in the presence of TNFa. HUVECs cultured in Basal conditions or with TNFa demonstrated intact tubular networks. However,
addition of NCCM at 10% signiﬁcantly decreased tubular length compared to TNFa controls, P ¼ 0.0009 (A) (error bars represent CI: Basal [224.9, 313.5], TNFa [244.1, 324.9],
NCCM10 þ TNFa [82.84, 141.1] and NCCM100 þ TNFa [107.1, 134.1]. Addition of CS at 10 mg and Noggin at 10 ng demonstrated similar effects, with signiﬁcant decreases in tubular
length compared to TNFa controls, P ¼ 0.0190, P ¼ 0.0149, respectively (B, C) (for CS, CI: Basal [224.9, 313.5], TNF [244.1, 324.9], CS10 þ TNF [94.56, 162.0] and CS100 þ TNF [77.28,
221.0] and for Noggin, CI: Basal [224.9, 313.5], TNF [244.1, 324.9], Nog10 þ TNF [93.62, 126.1] and Nog100 þ TNF [65.98, 259.7]. All scale bars correspond to 200 mm.
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effects in animal models of IVD degeneration45,46. This study
demonstrated that CS was able to inhibit HUVEC invasion and
tubular formation in the presence of TNFa. The ability of the pro-
teoglycan aggrecan to inhibit endothelial cell adhesion/migration
and nerve outgrowth depends on the degree of glycosylation8,29
suggesting that CS is largely responsible for the proteoglycan's
anti-angiogenic effects. These studies also demonstrated that there
were differences in the extent of inhibition induced by aggrecan
derived from AF and NP cells suggesting that studies examining
differences in the GAG proﬁles between NP cells and immature NCs
arewarranted. Blocking studies where NCCMwas depleted of intactTable I
Gene expression of Angiogenic factors form HUVECs treated with NCCM, CS, and Noggin w
treated with either NCCM (100%), CS at 100 mg/ml or Noggin 10 ng/ml in both Basal and
down-regulated all genes apart from IL-8 compared to Basal control (P ¼ 0.0256, P ¼ 0
signiﬁcant decreases in VEGF, MMP-7, IL-6 and IL-8 expression compared to the TNFa con
had no signiﬁcant effects on pro-angiogenic genes under both Basal and TNFa treated c
control. CI is given in parenthesize. Statistically signiﬁcant data is asterisked (P < 0.05)
Treatments VEGF MMP7
Basal Basal Control 1 (9.6, 9.3) 1 (13
NCCM ¡68.2 (37.4, 103.9)* ¡31.4 (
Noggin ¡7.4 (7.5, 11.6) ¡6.8 (
CS ¡3.0 (0.15, 6.7) ¡1.3 (
TNFa TNFa Control 1 (10.5, 10.3) 1 (11
NCCM 180.0 (35.6, 372.7)* 86.0 (
Noggin ¡3.0 (7.0, 10.7) ¡4.9 (1.
CS ¡26.6 (0.64, 61.5) ¡14.9 (0.CS restored cell invasion and tubular length back to basal levels
conﬁrming that CS was necessary for NCCM's inhibitory effects. We
have shown that CS can inhibit neural and vascular growth
simultaneously, making it an attractive treatment option and sug-
gesting that restoration of thematrix barrier rich in CS is likely to be
very important to repel and inhibit neurovascular ingrowth in
diseased IVDs.
Noggin is a BMP antagonist that is produced by the notochord
and is an essential mediator in patterning the spine during devel-
opment47. Noggin is known to have anti-angiogenic effects during
development and in vitro27. Such effects have been explained as
either (1) interruption of the BMP mediated VEGF promoter, andith and without TNFa. Gene expression of VEGF, MMP-7, IL-6 and IL-8 from HUVECs
TNFa treated conditions was quantiﬁed. Under Basal conditions, NCCM signiﬁcantly
.0201 and P ¼ 0.0283, respectively). In the presence of TNFa, NCCM demonstrated
trol (P ¼ 0.0140, P ¼ 0.0162, P ¼ 0.0346 and P ¼ 0.0346, respectively). Noggin and CS
onditions. Bolded number indicates fold change from control, either Basal or TNFa
IL-6 IL-8
.3, 13.5) 1 (11.1, 11.3) 1 (7.4, 7.9)
10.0, 57.7)* ¡58.8 (30.3, 92.1)* ¡12.2 (3.7, 22.9)
2.8, 11.7) ¡1.5 (0.8, 2.1) ¡2.7 (3.0, 3.7)
2.3, 3.8) ¡3.6 (6.2, 1.7) ¡0.6 (2.0, 1.6)
.3, 11.9) 1 (13.7, 14.2) 1 (17.5, 19.0)
28.6,-158.4)* 195 (86.9, 327.5)* 39.7 (18.9, 64.2)*
5, 26.4) 1.2 (4.0, 0.5) ¡1.7 (19.5, 28.7)
1, 36.6) ¡4.5 (4.6, 1.5) 4.5 (0.1, 10.4)
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down-regulation of E-cadherin via Lef1-mediated transcrip-
tion48,49. In our study we demonstrated that 10 ng/ml was the
optimal dose to inhibit both invasion and tubular formation in basal
and TNFa stimulated culture conditions. The fact that 100 ng did
not induce similar affects was surprising as Noggin has been shown
to have an inhibitory effect on endothelial tubular formation with
increased doses50. Differences may likely be attributed to slight
variations in the 3D matrices utilized such as Matrigel vs Geltrex.
Currently, there is no accepted method to directly block the func-
tion of Noggin in vitro, so only additive studies were performed.
We examined the expression of pro-angiogenic factors VEGF,
MMP-7, IL-6 and IL-8 in HUVECs treated with NCCM, CS and Noggin
to assess if each of these factors acted via similar pathways. NCCM
inhibited the expression of all genes assessed with greatest sup-
pression for VEGF, suggesting that NCCM may inhibit cell invasion
and tubular formation through the modulation of all of these pro-
angiogenic factors. VEGF can be described as the master regulator
of angiogenesis and is a key growth factor that stimulates prolif-
eration, migration, and tube formation of endothelial cells7. Inter-
estingly, CS and Noggin did not have any signiﬁcant effects on VEGF,
MMP-7, IL-6 or IL-8 expression suggesting that these ligands may
suppress angiogenesis through an alternative pathway such as
through inhibition of Cadherins or ligandematrix interactions49
and that other inhibiting factors, acting on VEGF, may be present
in NCCM.
This study addresses the high clinical need for a minimally
invasive therapy to treat discogenic back pain and we suggest that
neo-vascularization is an important clinical target.We demonstrate
for the ﬁrst time that soluble factors from NC-rich NP tissue are
capable of inhibiting angiogenesis in basal and pro-inﬂammatory
conditions as might be present in the degenerate micro-
environment. NCCM and candidate factors CS and Noggin demon-
strated anti-angiogenic effects on HUVECs and NCCM appeared to
act via the VEGF pathway. NCCM is not a feasible treatment option
highlighting a need to identify isolated factors from NCCM. CS has
the ability to inhibit both angiogenesis and innervation30, and may
be useful as a minimally invasive treatment option for discogenic
back pain, although precise mechanisms of action warrants further
investigation.
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